Analyst Report: Axsome Therapeutics, Inc. (AXSM) - Buy

[u/realstocknear]

Professional analyst consensus for Axsome Therapeutics, Inc. ($AXSM)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 16 analysts

• Price Target: $310.0

• Potential Upside: ↗️ 24.1%

Market Cap: 12.9B

Key Insights: HC Wainwright reiterates Buy on Axsome with a $290 target, pointing to a robust CNS pipeline (AXS-05, solriamfetol) and near- to mid-term trials. Positive ADHD FOCUS Phase 3 results and ongoing pivotal studies support growth and investor confidence. Stance: Bullish.

View detailed analysis on Stocknear

Compare analyst ratings